Public-Private Partnerships

Federal Republic of Germany

In 2010 the Federal Republic of Germany became the official hosting nation of the GISAID Initiative through a cooperation agreement realized by its Federal Ministry of Food and Agriculture (BMEL) overseeing technical hosting arrangements at the Federal Office for Agriculture and Food (BLE) and contributions through its Federal Research Institute for Animal Health, the Friedrich-Loeffler-Institute (FLI), a FAO and OIE Collaborating Center.


Under the Brazilian Ministry of Health in Rio de Janeiro, Fundação Oswaldo Cruz (FIOCRUZ) formalized its partnership with GISAID in 2020 through a research collaboration agreement which calls on FIOCRUZ's longstanding expertise to provide to the GISAID research community expertise through the improvement of outbreak data shared via the GISAID’s platform and its promotion of rapid sharing of such data for global public-health purposes.


Singapore's Agency for Science, Technology and Research (A*STAR) and its Bioinformatics Institute, entered in 2014 into a long-term cooperation agreement with GISAID on the integration and advancement of the FluSurver tool in EpiFlu™ and CoVsurver tool in EpiCoV™, to facilitate interpretation of adaptive changes and molecular evolution of influenza / coronaviruses and enhance surveillance.

United States of America

The United States Department of Health and Human Services, through its Centers for Disease Control and Prevention (CDC) is the first government to support the creation of the GISAID Initiative, by providing since 2007 technical guidance, public funding as well as substantial in-kind contributions for the ongoing development of the EpiFlu™ database application and GISAID's educational programs.

Sanofi Pasteur’s Foundation for Influenza Epidemiology

The Foundation’s Global Influenza Hospital-based Surveillance Network (GIHSN) was established to increase epidemiological evidence on the burden of severe influenza. In partnership with this initiative, GISAID will help promote the sharing and integration of clinical, epidemiological and virological data to better understand the impact of severe influenza and the benefit of vaccination.


Seqirus, a leading innovator in influenza vaccine technologies and pandemic response solutions, is a contributor to the GISAID public-private partnership, making it the first of its kind from the influenza industry. Seqirus’ commitment will bolster GISAID efforts to advance bioinformatics and the interpretation of influenza data.